MK-0608

Research use only, not for human use.

A nucleoside analogue that shows potent inhibition for replication of several mosquito-borne flaviviruses including DENV and ZIKV.

A nucleoside analogue that shows potent inhibition for replication of several mosquito-borne flaviviruses including DENV and ZIKV; also inhibits viral RNA replication in the subgenomic HCV genotype 1b replicon with EC50 of 0.3 uM, inhibits ZIKV viral polymerase both in vitro and in vivo.HCV Infection Phase 1 Discontinued.

——

Oral dosing of MK-0608 results in a potent antiviral effect. In preclinical pharmacokinetic experiments with rats, dogs, and rhesus monkeys, MK-0608 demonstrates good to excellent oral bioavailability (50 to 100%) and long plasma half-lives in dogs and rhesus macaques (9 and 14 h, respectively). Animal Model:The HCV-infected chimpanzees Dosage:1 mg/kg Administration:Administered orally; once daily for 37 days Result:Chimpanzee X6 had a baseline viral load that varied from 1,110 to 12,900 IU/mL, and chimpanzee X4 had a baseline viral load of 3×106 to 9×106 IU/mL.

MK 0608 | MK0608 | 2'-C-Methyl-7-deaza-adenosine | 7DMA

Microbiology/Virology

Filovirus

Filovirus

Infection

HCV Infection

443642-29-3

280.284

C12H16N4O4

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (891.97 mM)

NC1=C2C(N([C@H]3[C@]([C@@H]([C@@H](CO)O3)O)(C)O)C=C2)=NC=N1

(2R,3R,4R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol

(-20℃)

With Ice Pack

≥ 2 years